Wegovy 0.25mg: what does weight loss actually look like at this dose?

Why does 0.25mg Wegovy cause so little weight loss?

The 0.25mg dose of Wegovy exists for one reason: to give your digestive system a chance to adapt to semaglutide before the dose climbs. At this level, the GLP-1 receptor activation is real but mild, appetite suppression is minimal, gastric emptying is only slightly slowed, and most people notice little change in how hungry they feel day to day. Losing very little weight in the first four weeks is not a sign that the medicine is not working for you; it is a sign the schedule is working as intended.

The NHS semaglutide medicines page describes the step-up approach clearly: 0.25mg is explicitly listed as a starting dose, not a maintenance dose. Weight loss on 0.25mg Wegovy is rarely the story, adjustment is. If you have reached the four-week mark and seen no change on the scales, that puts you in the same position as the majority of people who started the same way and went on to meaningful results at higher doses.

What you may notice at 0.25mg is some nausea, particularly after meals, or mild changes in your appetite. These effects are typically gentler at 0.25mg than at any later point, which is precisely the design. Eating slowly, avoiding large portions and staying well hydrated helps most people through this phase. The detailed guide on no weight loss at 0.25mg Wegovy covers what to do if you are concerned or your prescriber has questions about continuing.

When does meaningful weight loss usually begin with Wegovy?

The clinical evidence for semaglutide 2.4mg (the standard maintenance dose) comes from the STEP 1 trial: a 68-week study of adults with obesity or overweight and at least one weight-related condition, which found an average body-weight reduction of around 15% compared with roughly 2.4% in the placebo group. That evidence was gathered at maintenance doses, not at 0.25mg. The published STEP 1 paper in the New England Journal of Medicine is the primary source behind NICE's recommendation of semaglutide for weight management.

For most people, appetite suppression becomes noticeable somewhere around the 0.5mg to 1.0mg mark, two to four months in. By the time a person reaches the 2.4mg maintenance dose, the combined effect on satiety, gastric emptying and food reward is substantially stronger than anything present at 0.25mg. Weight loss on 0.25mg Wegovy is therefore better understood as the beginning of a longer process, not a predictor of how the medicine will work for you overall.

If you want a clearer picture of what people experience further along the titration, the guide on weight loss at 0.5mg Wegovy covers the next step, and the page on 2.4mg Wegovy and weight loss sets out what the trial data shows at the maintenance level.

What side effects are most common at 0.25mg, and do they affect eating?

The most frequently reported effects at the 0.25mg starting dose are gastrointestinal: nausea, constipation, loose stools, burping and reflux. These are consistent with how GLP-1 receptor agonists work, slowing the movement of food through the stomach produces fullness signals but also, in some people, discomfort. The good news is that 0.25mg is the gentlest point in the schedule, so many people find these effects easier to manage here than later, after a dose increase.

Because nausea can reduce appetite, some people do lose a small amount of weight in the first four weeks simply by eating less. This is not the same as the medicine working at full effect, and it is not reliable or consistent. Dehydration from nausea or vomiting is worth taking seriously, if you are struggling to keep fluids down, that warrants a call to your prescriber rather than waiting for the next review.

One thing our prescribers hear regularly is that people worry a difficult first month means they are unusually sensitive to the medicine and should stop. Usually the opposite is true: GI symptoms at 0.25mg that are uncomfortable but manageable tend to settle by the time the dose has stabilised. Staying in contact with your clinical team through that adjustment period (rather than stopping and restarting) gives the schedule the best chance to work. You can find information on the full Wegovy dose schedule on the Wegovy doses overview page.

Does it matter that I have not lost weight yet, should I be worried?

Almost certainly not, if you are still at 0.25mg. The expected clinical outcome at this dose is tolerance, not transformation. That said, there are a few things worth keeping an eye on. If your prescriber has set a four-week review and you are approaching it, prepare to report any side effects honestly, including ones that felt minor. The review is also the point at which a dose increase is considered, so accurate reporting directly affects what happens next.

If, on the other hand, you have been on 0.25mg for longer than the prescribed period without a review being arranged, that is worth chasing up. The schedule is time-sensitive and delays at the starting dose simply delay the therapeutic effect. The Wegovy treatment overview explains how the medicine is intended to be used across the full titration period, and the 1mg Wegovy results page gives a realistic picture of what further dose steps tend to deliver.

For context on what treatment through a regulated private pharmacy involves (including how cost is structured and what is included) the weight-loss treatments page sets out the options clearly. If you would like a prescriber to review your suitability for Wegovy and discuss where you are in the process, you are welcome to start a free consultation with the team at nume.